ASSOCIATION OF ENDOMETRIOSIS WITH CARDIOVASCULAR EVENTS THE ROLE OF SYSTEMIC INFLAMMATION AND GONADOTROPIN RELEASING HORMONETHERAPY

In: Genetics and Molecular Research · 2026 · vol. 25(1s) · doi:10.4238/4ngd0539 · W7162753440
article OA: hybrid CC0

Abstract

The aim of the study was to evaluate the association of endometriosis in women of reproductive age with cardiovascular events, as well as to analyze the role of systemic inflammation and gonadotropin-releasing hormone (GnRH) agonist therapy.A single-center observational study was conducted that included 110 patients with laparoscopically confirmed endometriosis who were treated in a Novosibirsk hospital. Clinical and demographic characteristics, traditional cardiovascular risk factors, history of cardiovascular events, levels of highly sensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), as well as the presence and duration of GnRHagonist therapy were evaluated. The primary endpoint was a combined indicator, including myocardial infarction, ischemic stroke, transient ischemic attacks, episodes of unstable angina and hospitalization for hypertension decompensation. Cardiovascular events were reported in some patients and were associated with an older age, an increased body mass index, a higher incidence of hypertension, and more pronounced systemic inflammation in terms of hs-CRP, IL-6, and TNF-α levels. GnRH agonist therapy, especially with a duration of ≥ 6 months, was associated with an increased incidence of cardiovascular events. In a multivariate logistic regression, increased hs-CRP and long-term GnRHagonist therapy maintained an independent association with cardiovascular events after adjusting for age, body mass index, and hypertension. The results obtained emphasize the importance of endometriosis as a condition associated with increased cardiovascular risk, and indicate the important role of systemic inflammation and hormone therapy in the formation of an unfavorable cardiovascular profile in women of reproductive age. A comprehensive interdisciplinary approach involving a gynecologist and a cardiologist, early risk stratification and individualization of therapy are needed.
Full text 2,275 characters · extracted from oa-doi-fallback · click to expand
ASSOCIATION OF ENDOMETRIOSIS WITH CARDIOVASCULAR EVENTS THE ROLE OF SYSTEMIC INFLAMMATION AND GONADOTROPIN RELEASING HORMONETHERAPY DOI: https://doi.org/10.4238/4ngd0539Abstract The aim of the study was to evaluate the association of endometriosis in women of reproductive age with cardiovascular events, as well as to analyze the role of systemic inflammation and gonadotropin-releasing hormone (GnRH) agonist therapy.A single-center observational study was conducted that included 110 patients with laparoscopically confirmed endometriosis who were treated in a Novosibirsk hospital. Clinical and demographic characteristics, traditional cardiovascular risk factors, history of cardiovascular events, levels of highly sensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), as well as the presence and duration of GnRHagonist therapy were evaluated. The primary endpoint was a combined indicator, including myocardial infarction, ischemic stroke, transient ischemic attacks, episodes of unstable angina and hospitalization for hypertension decompensation. Cardiovascular events were reported in some patients and were associated with an older age, an increased body mass index, a higher incidence of hypertension, and more pronounced systemic inflammation in terms of hs-CRP, IL-6, and TNF-α levels. GnRH agonist therapy, especially with a duration of ≥ 6 months, was associated with an increased incidence of cardiovascular events. In a multivariate logistic regression, increased hs-CRP and long-term GnRHagonist therapy maintained an independent association with cardiovascular events after adjusting for age, body mass index, and hypertension. The results obtained emphasize the importance of endometriosis as a condition associated with increased cardiovascular risk, and indicate the important role of systemic inflammation and hormone therapy in the formation of an unfavorable cardiovascular profile in women of reproductive age. A comprehensive interdisciplinary approach involving a gynecologist and a cardiologist, early risk stratification and individualization of therapy are needed. Downloads Published Issue Section License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK